Type of publication:
Conference abstract
Author(s):
Kumar S.; *Rehman S.; *McCloud J.; *Clarke R.G.
Citation:
Colorectal Disease. Conference: Association of Coloproctology of Great Britain and Ireland Annual Meeting. Wales United Kingdom. 26(Supplement 1) (pp 71-72), 2024. Date of Publication: 01 Sep 2024.
Abstract:
Introduction: Trans-anal Endoscopic excision for Early Rectal Cancer (ERC) is low risk with excellent outcomes. Strict patient selection with discussion in an ERC MDT identifies appropriate patients for local excision. Trans-anal Endoscopic microsurgery (TEMS) with full-thickness excision is suitable for T1 rectal cancers as well as more advanced cancers in patients with significant comorbidity not fit for major surgery. We present results over a 10-year period. Method(s): We reviewed outcomes of patients undergoing TEMS for ERC, staged on MRI scans between March 2012 and Jan 2022 with follow up to Dec 2023. We included all patients withpotentially curable tumours and excluded patients deemed palliative at presentation. Result(s): 241 TEMS cases were performed with 73 for ERC with T1, T2 and T3 cancers being 70% (51/73), 24% (17/73) and 6% (5/73) respectively. Recurrence rates for T1 Cancer (Sm1, Haggit 1) was 0%. T1/2 with adverse histology was 18.7% to 41.7% and T3 was 80%. Resection margin R0 for T1 lesions was 86%-100% and for T2-T3 lesions was 20-60%. Correlation of T stage, resection margin and adverse histology to recurrence rates was significant. There were no major complications or deaths with 90 days. Conclusion(s): TEMS is a curative option for patients with ERC offering organ preservation and significantly less comorbidity than major resection. This is particularly important in the comorbid patient. Combination treatments with oncology can optimise outcomes in cancers with poor prognostic features and close surveillance will identify any local recurrence requiring salvage surgery.
DOI: 10.1111/codi.17066
